{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:39:44Z","timestamp":1784990384516,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clml.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T03:14:56Z","timestamp":1647918896000},"page":"e680-e684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u2018Fast but not so Furious\u2019: Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Youngberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Duco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.03.006_bib0001","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (Maia): overall survival results from a randomized, open-label, phase III trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.03.006_bib0002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): a randomized, open-label, phase III study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.03.006_bib0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.03.006_bib0004","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clml.2022.03.006_bib0005","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41375-018-0120-2","article-title":"Ninety-minute daratumumab infusion is safe in multiple myeloma","volume":"32","author":"Barr","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.03.006_bib0006","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (Columba): a multicentre, open-label, non-inferiority, randomized, phase III trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.03.006_bib0007","unstructured":"Darzalex (daratumumab) injection [package insert]. Titusville, NJ: Janssen Pharmaceutical Companies; 2019."},{"key":"10.1016\/j.clml.2022.03.006_bib0008","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (Pleiades): an open-label Phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.03.006_bib0009","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (Apollo): an open-label, randomized, phase III trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.03.006_bib0010","unstructured":"Darzalex Faspro (daratumumab hyaluronidase) injection [package insert]. Titusville, NJ: Janssen Pharmaceutical Companies; 2020."},{"key":"10.1016\/j.clml.2022.03.006_bib0011","series-title":"Successful conversion and implementation to subcutaneous daratumumab in patients with multiple myeloma (Mm) and light chain (Al) amyloidosis","first-page":"1975","volume":"138","author":"Hughes","year":"2021"},{"key":"10.1016\/j.clml.2022.03.006_bib0012","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1200\/JOP.18.00563","article-title":"National comprehensive cancer network infusion efficiency workgroup study: optimizing patient flow in infusion centers","volume":"15","author":"Sugalski","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clml.2022.03.006_bib0013","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.clml.2021.02.014","article-title":"Transition from intravenous to subcutaneous daratumumab formulation in clinical practice","volume":"21","author":"Hamadeh","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.03.006_bib0014","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1182\/blood-2021-153751","article-title":"Real-world observations and practical considerations of subcutaneous daratumumab administration in multiple myeloma","volume":"138","author":"Kim","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.03.006_bib0015","article-title":"Evaluation of subcutaneous daratumumab injections in the ambulatory care setting","author":"Tam","year":"2021","journal-title":"J Oncol Pharm Pract"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:09Z","timestamp":1761871209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502200088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S215226502200088X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.03.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Fast but not so Furious\u2019: Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}